Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Trevena Inc.
Age
18–79
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of congestive heart failure made at least 3 months prior to screening
NYHA Class III or IV heart failure, ejection fraction \</= 35% and , and in the opinion of the investigator, right-heart catheterization is clinically indicated.
Baseline mean PCWP \>/= 20 mmHg
Systolic blood pressure at screening must be \>/= 100 mmHg. Heart rate at screening must be \</= 90 bpm.
You may not be if
Any significant disease or condition that would interfere with the interpretation of safety or efficacy in this study as determined by the Investigator based on medical history, physical examination or laboratory tests.
Significant valve disease
Current signs or symptoms of acute myocardial ischemia or acute coronary syndrome (ACS) or coronary revascularization in the past 3 months.
Sustained or uncontrolled ventricular arrhythmia. Inclusion of patients with atrial fibrillation with a heart rate ≤ 90 bpm is permitted.
Clareo Health | Study to Evaluate the Effects of TRV120027 in Patients With Heart Failure
